Supernus Pharmaceuticals, Inc.
Frank Mottola (SVP, Chief Tech. Ops. Officer) reports SUPN insider transactions
About this filing
Supernus Pharmaceuticals, Inc. (SUPN) filed Form 4 (insider transaction) with the SEC on Nov 2, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Frank Mottola · SVP, Chief Tech. Ops. Officer
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | A · grantRestricted Stock UnitFootnotes F1 | +100,000 | $0.00 | $0.00 | 100,000 | Direct |
Footnotes
- F1 These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.
More SUPN filings
- 4
Filed Nov 2, 2026
- 4
Filed Nov 2, 2026
- 4
Filed Nov 2, 2026
- 4
Filed Nov 2, 2026
- 4
Filed Nov 2, 2026
- 8-K
Filed Nov 2, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.